Venous thromboembolism in bariatric surgery patients: an update of risk and prevention

Surgery for Obesity and Related Diseases

Volumn 3, Issue 1, 2007, Pages 97-102

  Hamad, Giselle G ^a   Bergqvist, David ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bariatric; Deep vein thrombosis; Low molecular weight heparin; Obesity; Prophylaxis; Pulmonary embolism

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; ESTROGEN DERIVATIVE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANTICOAGULANT THERAPY; BARIATRIC SURGERY; BLEEDING; CLINICAL TRIAL; COMPRESSION THERAPY; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; FILTER; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFERIOR CAVA VEIN; LUNG EMBOLISM; META ANALYSIS; MORBID OBESITY; OSTEOPOROSIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; SURGICAL MORTALITY; SURGICAL RISK; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BARIATRIC SURGERY; EARLY AMBULATION; HEPARIN; HUMANS; INTERMITTENT PNEUMATIC COMPRESSION DEVICES; OBESITY; PULMONARY EMBOLISM; RISK FACTORS; STOCKINGS, COMPRESSION; VENA CAVA FILTERS; VENOUS THROMBOSIS;

EID: 33846332060     PISSN: 15507289     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soard.2006.10.002     Document Type: Review

References (55)

1. Eriksson S., Backman L., and Ljungstrom K.G. The incidence of clinical postoperative thrombosis after gastric surgery for obesity during 16 years. Obes Surg 7 (1997) 332-336
2. Melinek J., Livingston E., Cortina G., and Fishbein M.C. Autopsy findings following gastric bypass surgery for morbid obesity. Arch Pathol Lab Med 126 (2002) 1091-1095
3. Sapala J.A., Wood M.H., Schuhknecht M.P., and Sapala M.A. Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. Obes Surg 13 (2003) 819-825
4. Westling A., Bergqvist D., Bostrom A., Karacagil S., and Gustavsson S. Incidence of deep venous thrombosis in patients undergoing obesity surgery. World J Surg 26 (2002) 470-473
5. Wu E.C., and Barba C.A. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. Obes Surg 10 (2000) 7-14
6. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292 (2004) 1724-1737
7. Flum D.R., Salem L., Elrod J.A., Dellinger E.P., Cheadle A., and Chan L. Early mortality among Medicare beneficiaries undergoing bariatric surgical procedures. JAMA 294 (2005) 1903-1908
8. Podnos Y.D., Jimenez J.C., Wilson S.E., Stevens C.M., and Nguyen N.T. Complications after laparoscopic gastric bypass: a review of 3464 cases. Arch Surg 138 (2003) 957-961
9. Prystowsky J.B., Morasch M.D., Eskandari M.K., Hungness E.S., and Nagle A.P. Prospective analysis of the incidence of deep venous thrombosis in bariatric surgery patients. Surgery 138 (2005) 759-765
10. Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 160 (2000) 3415-3420
11. Anderson Jr. F.A., and Spencer F.A. Risk factors for venous thromboembolism. Circulation 107 (2003) I9-I16
12. Poulose B.K., Griffin M.R., Zhu Y., et al. National analysis of adverse patient safety for events in bariatric surgery. Am Surg 71 (2005) 406-413
13. Institute for Clinical Systems Improvement. Prevention and management of obesity (mature adolescents and adults). 2nd ed. (2005). http://www.guideline.gov Available from http://www.guideline.gov. Accessed September 22, 2006
14. Ambrosetti M., Lucioni A., Ageno W., Conti S., and Neri M. Is venous thromboembolism more frequent in patients with obstructive sleep apnea syndrome?. J Thromb Haemost 2 (2004) 1858-1860
15. Arnulf I., Merino-Andreu M., Perrier A., Birolleau S., Similowski T., and Derenne J.P. Obstructive sleep apnea and venous thromboembolism. JAMA 287 (2002) 2655-2656
16. Hansson P.O., Eriksson H., Welin L., Svardsudd K., and Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: "the study of men born in 1913.". Arch Intern Med 159 (1999) 1886-1890
17. De Pergola G., De Mitrio V., Giorgino F., et al. Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes Relat Metab Disord 21 (1997) 527-535
18. Sugerman H.J., Sugerman E.L., Wolfe L., Kellum Jr. J.M., Schweitzer M.A., and DeMaria E.J. Risks and benefits of gastric bypass in morbidly obese patients with severe venous stasis disease. Ann Surg 234 (2001) 41-46
19. Schauer P.R., and Sirinek K.R. The laparoscopic approach reduces the endocrine response to elective cholecystectomy. Am Surg 61 (1995) 106-111
20. Holzheimer R.G. Laparoscopic procedures as a risk factor of deep venous thrombosis, superficial ascending thrombophlebitis and pulmonary embolism-case report and review of the literature. Eur J Med Res 9 (2004) 417-422
21. Nguyen N.T., Cronan M., Braley S., Rivers R., and Wolfe B.M. Duplex ultrasound assessment of femoral venous flow during laparoscopic and open gastric bypass. Surg Endosc 17 (2003) 285-290
22. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 338S-400S
23. Hamad G.G., and Choban P.S. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 15 (2005) 1368-1374
24. American College of Chest Physicians. Definitions of ACCP evidence-based guidelines, consensus statements, and other reviews and projects. Accessed September 29, 2006. Available from http://www.chestnet.org/education/guidelines/definitions.php.
25. Gonzalez Q.H., Tishler D.S., Plata-Munoz J.J., et al. Incidence of clinically evident deep venous thrombosis after laparoscopic Roux-en-Y gastric bypass. Surg Endosc 18 (2004) 1082-1084
26. Miller M.T., and Rovito P.F. An approach to venous thromboembolism prophylaxis in laparoscopic Roux-en-Y gastric bypass surgery. Obes Surg 14 (2004) 731-737
27. Ferrell A., Byrne T.K., and Robison J.G. Placement of inferior vena cava filters in bariatric surgical patients-possible indications and technical considerations. Obes Surg 14 (2004) 738-743
28. Keeling W.B., Haines K., Stone P.A., Armstrong P.A., Murr M.M., and Shames M.L. Current indications for preoperative inferior vena cava filter insertion in patients undergoing surgery for morbid obesity. Obes Surg 15 (2005) 1009-1012
29. Sugerman H.J. Special problems in obesity. In: Wilmore D.W., Brennan M.F., Harken A.H., Holcroft J.W., and Meakins J.L. (Eds). Care of the surgical patient (1989), American College of Surgeons, New York 3-11
30. Decousus H., Leizorovicz A., Parent F., et al., for the Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 338 (1998) 409-415
31. Lorch H., Welger D., Wagner V., et al. Current practice of temporary vena cava filter insertion: a multicenter registry. J Vasc Interv Radiol 11 (2000) 83-88
32. Kaufman J.A., Kinney T.B., Streiff M.B., et al. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. Surg Obes Relat Dis 2 (2006) 200-212
33. Offner P.J., Hawkes A., Madayag R., Seale F., and Maines C. The role of temporary inferior vena cava filters in critically ill surgical patients. Arch Surg 138 (2003) 591-595
34. Mismetti P., Laporte S., Darmon J.Y., Buchmuller A., and Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88 (2001) 913-930
35. Shepherd M.F., Rosborough T.K., and Schwartz M.L. Heparin thromboprophylaxis in gastric bypass surgery. Obes Surg 13 (2003) 249-253
36. Kalfarentzos F., Stavropoulou F., Yarmenitis S., et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obes Surg 11 (2001) 670-676
37. Scholten D.J., Hoedema R.M., and Scholten S.E. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 12 (2002) 19-24
38. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 188S-203S
39. Kucher N., Leizorovicz A., Vaitkus P.T., et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 165 (2005) 341-345
40. Al-Yaseen E., Wells P.S., Anderson J., Martin J., and Kovacs M.J. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost 3 (2005) 100-102
41. Barba R., Marco J., Martin-Alvarez H., et al. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost 3 (2005) 856-862
42. Bazinet A., Almanric K., Brunet C., et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 116 (2005) 41-50
43. Hainer J.W., Barrett J.S., Assaid C.A., et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 87 (2002) 817-823
44. Smith J., and Canton E.M. Weight-based administration of dalteparin in obese patients. Am J Health Syst Pharm 60 (2003) 683-687
45. Spinler S.A., Inverso S.M., Cohen M., Goodman S.G., Stringer K.A., and Antman E.M. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 146 (2003) 33-41
46. Frederiksen S.G., Hedenbro J.L., and Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 90 (2003) 547-548
47. Hamad G.G., Ikramuddin S., Posner M., Fernstrom J.D., Bontempo F., and Schauer P.R. Recommended dosing of enoxaparin for thromboprophylaxis is sub-therapeutic in the morbidly obese. Obes Surg 12 (2002) 213-214
48. Heizmann M., Baerlocher G.M., Steinmann F., Horber F.F., and Wuillemin W. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis. Thromb Res 106 (2002) 179-181
49. Sanderink G.J., Le Liboux A., Jariwala N., et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 72 (2002) 308-318
50. Quebbemann B., Akhondzadeh M., and Dalla R. Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients. Obes Surg 15 (2005) 1221-1224
51. Shepherd M.F., Rosborough T.K., and Schwartz M.L. Unfractionated heparin infusion for thromboprophylaxis in highest risk gastric bypass surgery. Obes Surg 14 (2004) 601-605
52. Huber O., Bounameaux H., Borst F., and Rohner A. Postoperative pulmonary embolism after hospital discharge: an underestimated risk. Arch Surg 127 (1992) 310-313
53. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest 124 (2003) 386S-392S
54. Bergqvist D., Agnelli G., Cohen A.T., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346 (2002) 975-980
55. Hull R.D., Pineo G.F., Stein P.D., et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 135 (2001) 858-869